Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: March 2011

FDA approves ipilimumab (Medarex/Bristol-Myers Squibb’s Yervoy) for treatment of metastatic melanoma

TweetOn March 25, 2011, the FDA approved ipilimumab (Medarex/Bristol-Myers Squibb’s [BMS’s] Yervoy) for treatment of unresectable or metastatic melanoma. The drug has been approved for patients with either newly-diagnosed or previously-treated disease. According to Richard Pazdur, the director of the FDA’s office of oncology drug products, none of the previously-approved treatments for metastatic melanoma, a…

For the people of Japan

TweetOn March 3, 2011, we posted an article on this blog on the acquisition of Plexxikon by Daiichi Sankyo. Then on March 11, 2001, came the 9.0-magnitude Tōhoku earthquake, followed by the devastating tsunami, with the loss of thousands of lives, and extensive damage to the infrastructure of Japan. Particularly troubling is the damage to…

Plexxikon acquired by Daiichi Sankyo

Tweet  On March 1, 2011, Plexxikon, Inc. (Berkeley, CA) announced that it has agreed to be acquired by Daiichi Sankyo, Japan’s third-largest pharmaceutical company, via an all-cash purchase. Under the merger agreement, Daiichi will pay $805 million up-front to purchase Plexxikon. Near-term milestone payments associated with the approval of Plexxikon’s lead drug candidate PLX4032 could…